Serogroup W Meningitis Outbreak at the Subdistrict Level, Burkina Faso, 2012

Laurence Cibrelus, Isaïe Medah, Daouda Koussoubé, Denis Yélbeogo, Katya Fernandez, Clément Lingani, Mamoudou Djingarey, Stéphane Hugonnet

In 2012, Neisseria meningitidis serogroup W caused a widespread meningitis epidemic in Burkina Faso. We describe the dynamic of the epidemic at the subdistrict level. Disease detection at this scale allows for a timelier response, which is critical in the new epidemiologic landscape created in Africa by the N. meningitidis A conjugate vaccine.

Since 2010 in sub-Saharan Africa, a meningococcal A conjugate vaccine (MenAfriVac; http://www.menngvax.org/) has been widely introduced to at-risk areas in the meningitis belt, resulting in a change in the epidemiology of meningococcal meningitis in the region (1,2). Fewer meningitis cases are now diagnosed, and large outbreaks of Neisseria meningitidis serogroup A are diminishing. Proportionally, more epidemics are caused by other meningococcal serogroups (e.g., serogroup W) that have less salient epidemic patterns, limiting detection through district-level surveillance and delaying intervention measures (3). World Health Organization guidelines for outbreak response in sub-Saharan Africa were revised in 2014 partly to address this issue (4). To ensure timelier intervention, the guidelines recommend that epidemic risk be assessed for populations of 30,000–100,000.

In 2010, MenAfriVac was introduced in Burkina Faso (5), and meningitis incidence was low in 2011; however, during February–April 2012, several epidemic foci occurred at the district level (6). This epidemic was the first in Burkina Faso since introduction of MenAfriVac and the second serogroup W epidemic in the country, occurring 10 years after the initial outbreak (7,8).

Meningitis outbreak dynamics are seldom studied on a small scale (e.g., at the subdistrict level). However, key information for improving detection of and response to epidemics can be learned from such analyses. To add to the current knowledge, we studied meningitis outbreak dynamics in areas of Kombissiri district, Burkina Faso, that were most severely affected by the 2012 epidemic.

The Study
The study was a collaborative effort of the Disease Control Department of the Burkina Faso Ministry of Health and the World Health Organization. District-level aggregated surveillance data (weeks 1–17, 2012) and official population data were used. At the subdistrict level, population and surveillance data (weeks 1–16, 2012) were collected from the Kombissiri district surveillance unit. Standards for meningitis surveillance were used (9). The weekly alert and epidemic status for Kombissiri and its subdistricts were determined by using the 2012 meningitis incidence thresholds and the 2014 revised guidelines, which have a lower alert threshold (4,9).

In 2005, subdistrict zones were created in Burkina Faso to improve disease surveillance accuracy and timeliness; districts were subdivided into zones of ≈30,000 persons (Table). Within these zones, population numbers are similar, unlike numbers in health facility (HF) catchment areas, which in Kombissiri range from 440 to 25,000 persons. In Burkina Faso, zone data are infrequently analyzed, except in Kombissiri (Figure 1).

On a national level, 13 (21%) of the 63 districts in Burkina Faso reached meningitis epidemic status in 2012 (Table; online Technical Appendix, http://wwwnc.cdc.gov/EID/article/21/11/15-0304-Techappl1.pdf). N. meningitidis serogroup W caused 82.6% (384/465) of confirmed cases in these districts, in which no reactive vaccination against this serogroup had been recently conducted. Kombissiri had the highest cumulative attack rate (CAR) and was affected longer than other districts. Of 136 suspected meningitis cases in Kombissiri, 44 (32%) were confirmed: 36 (82%) of those were caused by N. meningitidis serogroup W, 1 (2%) was caused by N. meningitidis serogroup X, and 7 (16%) were caused by Streptococcus pneumoniae. District- and subdistrict-level distributions of these pathogens were comparable.

The outbreak in Kombissiri reached alert and epidemic thresholds during weeks 7 and 11, respectively; a total of 9 weeks were spent in these phases (Table). At the subdistrict level, alert and epidemic thresholds were reached at weeks 1 and 3, respectively, 6 and 8 weeks, respectively, earlier than at the district level. Alert and epidemic thresholds were first crossed in zone 2, and contiguous zones were gradually crossed in zone 3 and zone 4. These zones were then crossed in zones 1 and 5, and the epidemic moved across the district of Kombissiri in 2 weeks (Figure 1). The epidemic moved to contiguous districts in 3 weeks and crossed district 1 in zone 2 in 5 weeks. To add...
affected from week 6 onward (Figure 2). Zones 1 and 2 (outbreak epicenters) were the only zones in the epidemic phase for >2 continuous weeks. In these zones, the average alert and epidemic phases were longer than those at the district level (12.5 vs. 9.0 weeks), the preepidemic phase was shorter (2.0 vs. 4.0 weeks), the time to peak was longer (6.5 vs. 1.0 weeks), and the epidemic phase started earlier (week 3 [zone 2] and week 8 [zone 1] vs. week 11) and was longer (10 vs. 3 weeks) (Table). The average CAR and peak incidence in zones 1 and 2 were higher than those for Kombissiri (CAR 223.3 vs. 105.2 cases/100,000 population; peak incidence 42.6 vs. 14.4 cases/week/100,000 population) and other districts (Table). The levels were also higher than those in 2012 serogroup W epidemics with district-level documentation in The Gambia (CAR 111 cases/100,000 population) and Benin (CAR 123.7 cases/100,000 population; peak incidence 16.7 cases/week/100,000 population) (10,11). If the 2014 recommendations for epidemic detection had been used in Kombissiri, the district-level preepidemic phase would have been 4 weeks longer, reaching the alert threshold in week 3 rather than 7 (13 weeks total in alert and epidemic phases). At the zone level, in the outbreak epicenter, the alert phase would have begun 1 week earlier in zone 1; no change would have been seen for zone 2, which was in the alert phase since week 1.

Conclusions

During the 2012 serogroup W meningitis epidemic in Burkina Faso, localized subdistrict epidemics occurred before those identified at the district level. Subdistrict epidemics were also of longer duration and greater intensity. At the subdistrict level, the epidemic spread from the 2 epicenter zones to other contiguous zones; several zones were affected before the district reached epidemic status.

If a subdistrict-level epidemic risk assessment had triggered district-level interventions in Kombissiri, meningitis surveillance and microbiologic testing could have been intensified (alert phase) and epidemic control measures could have been implemented (epidemic phase) up to 6 and 8 weeks earlier, respectively, by using
modifying the epidemic threshold; lowering the threshold might trigger unnecessary resource-intensive interventions, using limited vaccine supplies. However, modifications should be reconsidered once dynamics of non-serogroup A meningitis epidemics are better understood at the subdistrict level (4).

The advantages of reducing the spatial scale of epidemic risk assessment were recognized when *N. meningitidis* A was driving the epidemiology of meningitis in Africa and phenomena detected at HF level developed into large epidemics (13,14). However, outbreaks caused by non-A meningococcal meningitis serogroups have less resonant patterns, and analysis of the epidemic risk at a level within the subdistrict (e.g., HF level) may lack sensitivity (4). Nevertheless, it is essential that good quality data be readily available at that level for finer analysis when needed. The infrequent use of subdistrict-level data is partly due to their limited routine availability. Collection of subdistrict-level data was difficult when enhanced surveillance was the predominant approach for surveillance in the meningitis belt, but the transition toward case-based strategies (according to which meningitis cases are individually described at the HF level) should help fill this gap (9,15).

**Acknowledgments**

We are grateful to Etienne Traoré for his commitment and insight throughout this investigation. We thank Souleymane Sanou, Félix Tarbangdo, Massata Nikiema, Lydie Kaboré, Mohamed Tall, Boulaye Dao, Eloi Silga, Ernest Kompaoré, Adama Bontogo, Rasmata Ouédraogo-Traoré, Mamadou Tamboura, Dinanibé Kambiré, and William Perea for sharing expertise and providing advice.

L.C., K.F., C.L., M.D, and S.H. are responsible for views expressed in this article, which do not necessarily represent the decisions, policy, or views of the World Health Organization.

Dr. Cibrelus is a medical epidemiologist. Her primary research interests include risk assessment, surveillance, and control of communicable diseases, such as meningococcal meningitis.
References

1. Lapeyssonnie L. Cerebrospinal meningitis in Africa [in French]. Bull World Health Organ. 1963;28(Suppl):1–114.
2. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med. 2011;364:2293–304. http://dx.doi.org/10.1056/NEJMoa1003812
3. World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012—emerging needs and future perspectives. Wkly Epidemiol Rec. 2013;88:129–36.
4. World Health Organization. Meningitis outbreak response in sub-Saharan Africa: WHO guideline. 2014 [cited 2015 Jan 22]. http://apps.who.int/iris/bitstream/10665/144727/1/WHO_HSE_PED_CED_14_5_eng.pdf?ua=1
5. Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012;12:757–64. http://dx.doi.org/10.1016/S1473-3099(12)70168-8
6. MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FV, et al. Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis. 2014;20:394–9. http://dx.doi.org/10.3201/eid2003.131407
7. Koumaré B, Ouédraogo-Traoré R, Sanou I, Yada AA, Sow I, Lusamba PS, et al. The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002. Vaccine. 2007;25(Suppl 1):A37–41. http://dx.doi.org/10.1016/j.vaccine.2007.04.038
8. Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlow E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007;13:920–3. http://dx.doi.org/10.3201/eid1306.060940
9. World Health Organization. Detecting meningococcal meningitis epidemics in highly endemic African countries. Wkly Epidemiol Rec. 2000;75:306–9.
10. Hossain MJ, Roca A, Mackenzie GA, Jasseh M, Hossain MI, Muhammad S, et al. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerg Infect Dis. 2013;19:1507–10. http://dx.doi.org/10.3201/eid1909.130077
11. Njampho-Lafourcade BM, Hugonnet S, Djogbe H, Kodjo A, N’Doubra AK, Taha MK, et al. Mobile microbiological laboratory support for evaluation of a meningitis epidemic in northern Benin. PLoS ONE. 2013;8:e68401. http://dx.doi.org/10.1371/journal.pone.0068401
12. Leake JAD, Kone ML, Yada AA, Barry LF, Traore G, Ware A, et al. Early detection and response to meningococcal disease epidemics in sub-Saharan Africa: appraisal of the WHO strategy. Bull World Health Organ. 2002;80:342–9.
13. Tall H, Hugonnet S, Donnen P, Dramaix-Wilmet M, Kambou L, Drabo F, et al. Definition and characterization of localised meningitis epidemics in Burkina Faso: a longitudinal retrospective study. BMC Infect Dis. 2012;12:2. http://dx.doi.org/10.1186/1471-2334-12-2
14. Paireau J, Girond F, Collard JM, Mainassara HB, Jusot JF. Analysing spatio-temporal clustering of meningococcal meningitis outbreaks in Niger reveals opportunities for improved disease control. PLoS Negl Trop Dis. 2012;6:e1577.
15. Epidemic meningitis surveillance in the African meningitis belt, deciding on the most appropriate approach. 2014 [cited 2015 Jan 05]. http://www.who.int/csr/resources/publications/meningitis/HSE_PED_CED_2014/en/

Address for correspondence: Katya Fernandez, Epidemic and Pandemic Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland; email: fernandezk@who.int